Oxpentifylline, tumour necrosis factor-alpha and Crohn's disease

Affiliations

Comment

T T MacDonald. Gut. 1997 Apr.

. 1997 Apr;40(4):559.

doi: 10.1136/gut.40.4.559.

¹ Department of Paediatric Gastroenterology, St Bartholomews and the Royal London School of Medicine and Dentistry, London.

No abstract available

Comment on

Tumour necrosis factor and Crohn's disease.
Van Deventer SJ. Van Deventer SJ. Gut. 1997 Apr;40(4):443-8. doi: 10.1136/gut.40.4.443. Gut. 1997. PMID: 9176068 Free PMC article. Review. No abstract available.
Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease.
Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Bauditz J, et al. Gut. 1997 Apr;40(4):470-4. doi: 10.1136/gut.40.4.470. Gut. 1997. PMID: 9176073 Free PMC article. Clinical Trial.
In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, Poindron P, Duclos B. Reimund JM, et al. Gut. 1997 Apr;40(4):475-80. doi: 10.1136/gut.40.4.475. Gut. 1997. PMID: 9176074 Free PMC article.